Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rare, aggressive NSCLC type yields to pembrolizumab

Publish date:: March 4, 2019

Key clinical point: Pulmonary sarcomatoid carcinomas are extremely sensitive to anti–programmed death-ligand 1 therapy.

Major finding: The objective response rate was 80% and clinical benefit rate was100%.

Study details: A retrospective case series of five patients plus historical patients for comparison purposes.

Disclosures: The study was internally funded. Dr. Sukrithan reported having no disclosures.

Citation:

Sukrithan V et al. ASCO-SITC, Abstract 115.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lung Cancer

Two different radiation boost strategies reduce local failures in NSCLC,

Rechallenge ‘reasonable’ for some with small-cell lung cancer,

Black patients with ES-SCLC get less chemo but have better survival,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,